Drug Profile
Camlipixant - BELLUS Health
Alternative Names: BLU-5937; GSK-5464714; NEO 5937Latest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer BELLUS Health
- Class Antipruritics; Antitussives; Imidazoles; Pyridines; Small molecules
- Mechanism of Action Purinergic P2X3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cough
- Discontinued Pruritus
Most Recent Events
- 23 Jan 2024 GlaxoSmithKline plans a phase I pharmacokinetic trial in subjects with normal and impaired hepatic function (In Volunteers) in January 2024 (NCT06222892)
- 19 Jan 2024 Bellus Health initiates a phase I pharmacokinetic trial in subjects with normal and impaired hepatic function (In Volunteers) (PO) (NCT06222892)
- 13 Oct 2023 Bellus Health completes a phase-I drug-drug interactions trial (In volunteers) in Canada (PO, Tablet) (NCT05959447),